PPT-Module 9: HER2-Positive and

TripleNegative Breast Cancer Jamie Carroll APRN MSN CNP Hope S Rugo MD Disclosures for Ms Carroll No financial interests or affiliations to disclose Disclosures for Dr Rugo Contracted Research. First . Line and Beyond. Moderator:. Joseph Gligorov, MD, . PhD . Head, Cancer . Coordination Center . HUEP. University . Cancer . Institute. Sorbonne University. Paris. , . France. Panelist:. Carlos H. Barrios, . Clinical Practice Guideline Update. American Society of Clinical Oncology /. College of American Pathologists . www.asco.org/guidelines/. © American . Society of Clinical Oncology®.  All rights reserved.. ASCO-CAP Recommendations For HER2 Testing in Breast Cancer. Criteria For Reporting HER2 Test Results . as Positive. Criteria for Reporting HER2 Test Results . as Negative. Criteria for Reporting Equivocal Results . Contents PageIntended Use 4Summary and Explanation -Breast 5Background 5Characteristics 5Principle of Procedure -Breast 5Reagents -Breast 6Materials provided 6Materials required but not provided 7Stor Heather M. Gage, MD, Avanti . Rangnekar. , Robert E. Heidel, . PhD. , Timothy Panella, MD, John Bell, MD, and Amila Orucevic, MD, . PhD. The Graduate School of Medicine. The Department of Pathology. Introduction. Luminal B-like (HER2-positive):!ER-positive!HER2-positive!Any Ki67 ** Aggressive phenotypes: TNBC or HER2-positive breast cancer!If ChTis planned, it should all be given as neoadjuvant"Concomitant pos in Development for . Breast Cancer. Sara A. Hurvitz, MD, FACP. Professor of Medicine. David Geffen School of Medicine, UCLA. Los Angeles, CA. William J. Gradishar, MD, FASCO, FACP. Betsy Bramsen Professor of Breast Oncology & Professor of Medicine. Sara A. Hurvitz, MD, FACP. Professor of Medicine. David Geffen School of Medicine, UCLA. Los Angeles, CA. William J. Gradishar, MD, FASCO, FACP. Betsy Bramsen Professor . of Breast Oncology . & Professor of Medicine. Breast Cancer . Elizabeth O’Reilly, MSN, MPH, ANP-BC. Sara . Hurvitz. , MD. Disclosures for . Ms. O’Reilly. No financial interests or affiliations to disclose. Disclosures for Dr . Hurvitz. Salary: . Bidstrup. Mrs B is a 49 . yo. woman who attended for a regular 3 weekly review and Herceptin dose. Intro. Dec 2000: . attended GP regarding lump that had been present in L) breast for 6/12. . Bx. - breast ca. ishtiaq. . FCPS R3 general surgery unit one UKSO . prof . tariq. . ghaffor. . sb. . . Objectives. Surgical Anatomy. Investigations. Diagnosis. Percent with Patients. Number of Patients (Median). ER-positive, HER2-negative breast cancer for whom you ordered a genomic assay. 92. 14. Metastatic ER-positive, HER2-negative . breast cancer. 96. 10. Trastuzumab-emtansine. : A . very. . nice. . poison. T-DM1 (. Trastuzumab. – . emtansine. ). Pre-Clinical and Early Clinical Development. May. , 2014. Overview. Anti HER2 therapy in . mBC. . –. breast. . cancer. . needs. . different. . therapeutic. . strategies. . than. HER-2 . enriched. . tumors. ?. Patrizia Vici. Cleopatra. TDM-1: . EMILIA. Verma. S ESMO 2012. (. Activity. . HR+.